News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,777 Results
Type
Article (14068)
Company Profile (282)
Press Release (249427)
Section
Business (79436)
Career Advice (152)
Deals (13215)
Drug Delivery (34)
Drug Development (50383)
Employer Resources (31)
FDA (5699)
Job Trends (5121)
News (144257)
Policy (10023)
Tag
Academia (901)
Alliances (21595)
Alzheimer's disease (785)
Antibody-drug conjugate (ADC) (71)
Approvals (5688)
Artificial intelligence (91)
Bankruptcy (101)
Best Places to Work (4559)
Biotechnology (232)
Breast cancer (124)
Cancer (1056)
Cardiovascular disease (85)
Career advice (132)
CAR-T (86)
Cell therapy (250)
Clinical research (40463)
Collaboration (412)
Compensation (169)
COVID-19 (1020)
C-suite (107)
Cystic fibrosis (74)
Data (1080)
Diabetes (101)
Diagnostics (1255)
Earnings (29109)
Events (47548)
Executive appointments (334)
FDA (6162)
Funding (389)
Gene editing (74)
Gene therapy (189)
GLP-1 (336)
Government (1071)
Healthcare (6565)
Infectious disease (1068)
Inflammatory bowel disease (100)
IPO (7239)
Job creations (859)
Job search strategy (127)
Layoffs (195)
Legal (1381)
Lung cancer (158)
Manufacturing (98)
Medical device (2569)
Medtech (2570)
Mergers & acquisitions (6194)
Metabolic disorders (304)
Neuroscience (1086)
NextGen: Class of 2025 (2013)
Non-profit (852)
Northern California (1264)
Obesity (164)
Opinion (95)
Parkinson's disease (88)
Patents (75)
People (25296)
Phase I (14287)
Phase II (18824)
Phase III (11892)
Pipeline (472)
Postmarket research (852)
Preclinical (5988)
Radiopharmaceuticals (209)
Rare diseases (237)
Real estate (1411)
Regulatory (8389)
Research institute (932)
Series A (75)
Southern California (1139)
Startups (1968)
United States (10079)
Vaccines (187)
Weight loss (94)
Date
Today (36)
Last 7 days (346)
Last 30 days (1533)
Last 365 days (20415)
2025 (1952)
2024 (20553)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Asia (17050)
Australia (2885)
California (2897)
Canada (921)
China (256)
Colorado (111)
Connecticut (120)
Delaware (66)
Europe (36693)
Florida (332)
Georgia (86)
Illinois (187)
Indiana (70)
Maryland (382)
Massachusetts (2305)
Minnesota (114)
New Jersey (720)
New York (795)
North Carolina (459)
Northern California (1264)
Ohio (93)
Pennsylvania (550)
South America (207)
Southern California (1139)
Texas (324)
Washington State (280)
263,777 Results for "vividion therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
January 22, 2025
·
3 min read
Press Releases
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
January 8, 2025
·
6 min read
Press Releases
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
October 8, 2024
·
3 min read
Biotech Beach
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
Vividion Therapeutics, Inc. today announced a landmark publication in Nature.
April 25, 2024
·
4 min read
Bio NC
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.
May 14, 2024
·
3 min read
Drug Development
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
February 6, 2024
·
6 min read
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune
Vividion Therapeutics, Inc. has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row.
November 21, 2023
·
4 min read
Business
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
Vividion Therapeutics, Inc. and a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Shawn Rose, M.D. Ph.D., has joined the company as Chief Development Officer, Immunology, reporting to our Chief Executive Officer, Aleksandra Rizo.
September 7, 2023
·
4 min read
Business
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
Vividion Therapeutics, Inc. today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.
March 23, 2023
·
4 min read
Business
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.
October 12, 2022
·
5 min read
1 of 26,378
Next
